CoChat

Clinical impact of tumor‐infiltrating lymphocytes for survival in stage II colon cancer

Open access
Lee, Won‐Suk, Park, Sanghui, Lee, Woo Yong, Yun, Seong Hyeon, Chun, Ho‐Kyung · 2010 · Cancer
Cited by 121

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The most reliable prognostic factor in colon cancer is the TNM classification. The objective of this study was to assess and compare the prognostic role of tumor‐infiltrating lymphocytes (TILs) in stage II colon cancer. METHODS: Immunohistochemistry was used to assess the density of TILs that were positive for cluster of differentiation 3 (CD3) (T‐cell coreceptor), CD45 isoform RO (CD45RO) (protein tyrosine phosphatase), nuclear transcription factor forkhead box P3 (FOXP3), and CD25 (a type I transmembrane protein) according to tumor site (intraepithelial and stromal) in samples from 87 patients who had stage II colon cancer. These variables were evaluated for their association with histopathologic features along with overall survival (OS) and disease‐free survival (DFS). RESULTS: Intraepithelial CD3‐posititve (CD3+), CD45RO+, CD25+, and FOXP3+ TILs were associated significantly with better DFS (P = .049, P = .009, P = .013, and P = .001, respectively). The estimated 5‐year OS rates for patients who had high‐density CD45RO+ and FOXP3+ expression was 100% for both compared with 79.2% and 78.8% for patients who had low‐density CD45RO+ and FOXP3+ expression (P = .017 and P = .040, respectively). A significant prognostic factor for both OS and DFS was high‐density stromal CD45RO+ lymphocytic infiltration (OS: P = .031; relative risk [RR], 0.134; 95% confidence interval [CI], 0.015‐1.164; DFS: P = .013; RR, 0.198; 95% CI, 0.055‐0.710); whereas intraepithelial FOXP3+ expression was an independent prognostic factor for DFS (P = .032; RR, 0.108; 95% CI, 0.014‐0.821). CONCLUSIONS: FOXP3+ and CD45RO+ TILs demonstrated independent prognostic significance for survival in the current investigation. These results may help to improve the prognostication of early stage colon cancer. Cancer 2010. © 2010 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.25293

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Cancer Statistics, 2003

    Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275

  • Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer

    Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×

    “T cells that were positive for the protein tyrosine phosphatase CD45 isoform RO (CD45RO) also reportedly had prognostic significance.(14,15) Oberg et al(14) reported that a high density of CD45RO-positive T cells in lymph node metastases from colon cancer was associated with an improved prognosis, and Pages et al(15)…”
    Background

Cited by

See all 121

Metadata

Authors
Lee, W., Park, S., Lee, W. Y., Yun, S. H., & Chun, H.
Venue
Cancer
Publisher
Wiley
Published
2010-11-03
Volume
116
Issue
22
Pages
5188-5199
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2032004084
Cited by
121
References
2
FWCI
4.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.